TY - JOUR
T1 - Liver-directed surgery for metastatic squamous cell carcinoma to the liver
T2 - Results of a multi-center analysis
AU - Pawlik, Timothy M.
AU - Gleisner, Ana Luiza
AU - Bauer, Todd W.
AU - Adams, Reid B.
AU - Reddy, Srinevas K.
AU - Clary, Bryan M.
AU - Martin, Robert C.
AU - Scoggins, Charles R.
AU - Tanabe, Kenneth K.
AU - Michaelson, James S.
AU - Kooby, David A.
AU - Staley, Charles A.
AU - Schulick, Richard D.
AU - Vauthey, Jean Nicolas
AU - Abdalla, Eddie K.
AU - Curley, Steven A.
AU - Choti, Michael A.
AU - Elias, Dominque
PY - 2007/10
Y1 - 2007/10
N2 - Background: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown. The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver. Methods: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers. Clinicopathologic factors were analyzed with regard to disease-free survival (DFS) and overall survival (OS). Results: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7). Treatment of primary SCC was chemotherapy ± radiotherapy alone (n = 29), chemotherapy ± radiotherapy + surgery (n = 15), or surgery alone (n = 8). Forty-seven patients underwent resection alone, 2 resection + radiofrequency ablation (RFA), and 3 RFA only. At last follow-up, 33 (63.5%) patients had recurred. The median time to recurrence was 9.8 months, and 5-year DFS was 18.6%. Factors associated with reduced DFS were liver tumor size > 5 cm (hazard ratio (HR) = 2.02) and positive surgical margin (HR = 2.33). The overall median survival after hepatic resection was 22.3 months and 5-year actuarial OS was 20.5%. Risk factors associated with worse overall survival included synchronous disease (HR = 4.09), hepatic metastasis > 5 cm (HR = 1.71) and positive surgical resection margin (HR = 1.83). Conclusions: The majority of patients will recur following hepatic resection of SCC. Long-term survival, however, can be achieved following surgical resection of SCC liver metastasis, especially in patients who present with limited metachronous disease amenable to margin negative resection.
AB - Background: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown. The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver. Methods: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers. Clinicopathologic factors were analyzed with regard to disease-free survival (DFS) and overall survival (OS). Results: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7). Treatment of primary SCC was chemotherapy ± radiotherapy alone (n = 29), chemotherapy ± radiotherapy + surgery (n = 15), or surgery alone (n = 8). Forty-seven patients underwent resection alone, 2 resection + radiofrequency ablation (RFA), and 3 RFA only. At last follow-up, 33 (63.5%) patients had recurred. The median time to recurrence was 9.8 months, and 5-year DFS was 18.6%. Factors associated with reduced DFS were liver tumor size > 5 cm (hazard ratio (HR) = 2.02) and positive surgical margin (HR = 2.33). The overall median survival after hepatic resection was 22.3 months and 5-year actuarial OS was 20.5%. Risk factors associated with worse overall survival included synchronous disease (HR = 4.09), hepatic metastasis > 5 cm (HR = 1.71) and positive surgical resection margin (HR = 1.83). Conclusions: The majority of patients will recur following hepatic resection of SCC. Long-term survival, however, can be achieved following surgical resection of SCC liver metastasis, especially in patients who present with limited metachronous disease amenable to margin negative resection.
KW - Hepatic resection
KW - Prognosis
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=34648829045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34648829045&partnerID=8YFLogxK
U2 - 10.1245/s10434-007-9467-8
DO - 10.1245/s10434-007-9467-8
M3 - Article
C2 - 17551795
AN - SCOPUS:34648829045
SN - 1068-9265
VL - 14
SP - 2807
EP - 2816
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 10
ER -